A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies
Status:
Completed
Trial end date:
2021-01-13
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety of ramucirumab plus MEDI4736 in
participants with locally advanced and unresectable or metastatic gastrointestinal or
thoracic malignancies including gastric or gastroesophageal junction (GEJ) adenocarcinoma,
non-small cell lung cancer (NSCLC), or hepatocellular carcinoma (HCC).